Kevin McCulloch - Apr 2, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Apr 2, 2025
Transactions value $
-$3,775
Form type
4
Date filed
4/3/2025, 04:20 PM
Previous filing
Feb 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability -$3.77K -733 -0.04% $5.15 1.68M Apr 2, 2025 Direct F1
holding XERS Common Stock 25K Apr 2, 2025 By Spouse F2
holding XERS Common Stock 2K Apr 2, 2025 By Charles R. McCulloch Trust dated 1990 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of April 2, 2025.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer